In gynecological cancers, the interaction between PRL and the prolactin receptor (PRLR) mainly promotes protumoral events, such as migration, invasion, metastasis, chemoresistance, inhibition of apoptosis, among others, through the activation of different signaling pathways and effector proteins, which will be addressed later. This evidence concerns the gene PRLR and female reproductive organ cancer.